PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES

被引：0
|
作者：
Davids, M. S. [1 ]
Seymour, J. F. [2 ]
Gerecitano, J. F. [3 ]
Kahl, B. S. [4 ]
Pagel, J. M. [5 ]
Wierda, W. G. [6 ]
Anderson, M. A. [7 ,8 ]
Rudersdorf, N. K. [9 ]
Gressick, L. A. [9 ]
Montalvo, N. P. [9 ]
Yang, J. [9 ]
Zhu, M. [9 ]
Dunbar, M. [9 ]
Cerri, E. [9 ]
Enschede, S. H. [9 ]
Humerickhouse, R. A. [9 ]
Roberts, A. W. [7 ,8 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Univ Texas Houston, Houston, TX USA
[7] Royal Melbourne Hosp, Melbourne, Vic, Australia
[8] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia
[9] AbbVie, N Chicago, IL USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1348
引用
收藏
页码：525 / 525
页数：1
相关论文
共 50 条
  • [21] Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Ansell, Stephen M.
    Witzig, Thomas E.
    Inwards, David J.
    Porrata, Luis F.
    Ythier, Arnaud
    Ferrande, Lee
    Nestorov, Ivan
    Devries, Todd
    Dillon, Stacey R.
    Hausman, Diana
    Novak, Anne J.
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1105 - 1110
  • [22] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)
    Younes, Anas
    Salles, Gilles
    Martinelli, Giovanni
    Bociek, R. Gregory
    Barrigon, Dolores Caballero
    Gonzalez Barca, Eva
    Turgut, Mehmet
    Gerecitano, John F.
    Herbst, Fabian
    Williams, Lisa
    Mukherjee, Nabanita
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2015, 126 (23)
  • [23] Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
    Herrera, Alex F.
    Chen, Lu
    Popplewell, Leslie L.
    Budde, Lihua E.
    Mei, Matthew
    Armenian, Saro H.
    Darrah, Justin
    Nikolaenko, Liana
    Chen, Robert W.
    Peters, Lacolle
    Kennedy, Neena
    Rosen, Steven
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2019, 134
  • [24] Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL)
    De Vos, Sven
    Flowers, Christopher
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan Hale
    Reid, Erin G.
    Cordero, Jaclyn
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Salem, Ahmed H.
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod
    Kozloff, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study
    Ma, Shuo
    Brander, Danielle M.
    Seymour, John F.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Davids, Matthew S.
    Anderson, Mary Ann
    Choi, Michael Y.
    Tam, Constantine S.
    Mason-Bright, Tanita
    Prine, Betty
    Munasinghe, Wijith
    Zhu, Ming
    Kim, Su Young
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2015, 126 (23)
  • [26] Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Heyman, Benjamin
    Rizzieri, David
    Adams, David J.
    De Castro, Carlos
    Diehl, Louis
    Li, Zhiguo
    Moore, Joseph
    Beaven, Anne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10): : 679 - 686
  • [27] Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
    Salles, Gilles
    Gopal, Ajay K.
    Minnema, Monique C.
    Wakamiya, Karen
    Feng, Huaibao
    Schecter, Jordan M.
    Wang, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 275 - 284
  • [28] Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Uchida, Toshiki
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Watanabe, Takashi
    Kasai, Masanobu
    Matsumoto, Yosuke
    Shimizu, Daisuke
    Ogawa, Yoshiaki
    Ohmachi, Ken
    Yokoyama, Hiroki
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2054 - 2058
  • [29] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Crombie, Jennifer L.
    Kim, Austin I.
    Bartlett, Nancy L.
    Redd, Robert A.
    Patterson, Victoria
    Carey, Celeste
    Balasubramanian, Sobana
    Odejide, Oreofe O.
    Merryman, Reid W.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Fisher, David C.
    Herrera, Alex F.
    Davids, Matthew S.
    Shipp, Margaret A.
    Armand, Philippe
    Shouse, Geoffrey P.
    BLOOD, 2023, 142
  • [30] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
12345